✦ LIBER ✦

Activity of Single-Agent Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors

✍ Scribed by Turnbull, James D.; Cobert, Julien; Jaffe, Tracy; Harrison, Michael R.; George, Daniel J.; Armstrong, Andrew J.

Book ID: 121231043
Publisher: CIG Media Group, LP.
Year: 2013
Tongue: English
Weight: 345 KB
Volume: 11
Category: Article
ISSN: 1558-7673
DOI: 10.1016/j.clgc.2012.06.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High Frequency of Intracerebral Hemorrha

High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor

✍ Damien Pouessel; Stéphane Culine 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Efficacy and safety of vascular endothel

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features

✍ Jae-Lyun Lee; Inkeun Park; Kwonoh Park; Seongjoon Park; Yongcheol Ahn; Jin-Hee A 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 317 KB

Are Tyrosine Kinase Inhibitors Still Act

Are Tyrosine Kinase Inhibitors Still Active in Patients With Metastatic Renal Cell Carcinoma Previously Treated With a Tyrosine Kinase Inhibitor and Everolimus? Experience of 36 Patients Treated in France in the RECORD-1 Trial

✍ Blesius, Aurore; Beuselinck, Benoit; Chevreau, Christine; Ravaud, Alain; Rolland 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 303 KB

Clinical factors associated with outcome

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

✍ Toni K. Choueiri; Jorge A. Garcia; Paul Elson; Mohamad Khasawneh; Saif Usman; Al 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract ## BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell carcinoma (RCC). The identification of patients who are more likely to benefit from these agents is warranted. ## METHODS. In to

Sarcomatoid Dedifferentiation in Metasta

Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis

✍ Beuselinck, Benoit; Lerut, Evelyne; Wolter, Pascal; Dumez, Herlinde; Berkers, Jo 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 163 KB

A “Game of Thrones” in Metastatic Renal

A “Game of Thrones” in Metastatic Renal Cell Carcinoma: Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors and Mammalian Target of Rapamycin Inhibitors Battling for Position

✍ Pal, Sumanta Kumar; Vogelzang, Nicholas J. 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 471 KB